306 related articles for article (PubMed ID: 10326698)
41. [Is hereditary predisposition to breast cancer linked to BRCA1 a disease of response to genotoxic lesions?].
Feunteun J
C R Seances Soc Biol Fil; 1998; 192(2):235-40. PubMed ID: 9759367
[TBL] [Abstract][Full Text] [Related]
42. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.
Rodríguez-Pinilla SM; Sarrió D; Honrado E; Hardisson D; Calero F; Benitez J; Palacios J
Clin Cancer Res; 2006 Mar; 12(5):1533-9. PubMed ID: 16533778
[TBL] [Abstract][Full Text] [Related]
44. Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.
Okada S; Tokunaga E; Kitao H; Akiyoshi S; Yamashita N; Saeki H; Oki E; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 May; 19(5):1499-507. PubMed ID: 22179631
[TBL] [Abstract][Full Text] [Related]
45. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer.
Eisinger F; Stoppa-Lyonnet D; Longy M; Kerangueven F; Noguchi T; Bailly C; Vincent-Salomon A; Jacquemier J; Birnbaum D; Sobol H
Cancer Res; 1996 Feb; 56(3):471-4. PubMed ID: 8564955
[TBL] [Abstract][Full Text] [Related]
46. HMGA1 protein expression in familial breast carcinoma patients.
Chiappetta G; Ottaiano A; Vuttariello E; Monaco M; Galdiero F; Gallipoli A; Pilotti S; Jodice G; Siranoush M; Colombo M; Ripamonti CB; Pallante PL; Radice P; Fusco A
Eur J Cancer; 2010 Jan; 46(2):332-9. PubMed ID: 19896837
[TBL] [Abstract][Full Text] [Related]
47. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
[TBL] [Abstract][Full Text] [Related]
48. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
Rayoo M; Yan M; Takano EA; Bates GJ; Brown PJ; Banham AH; Fox SB
J Clin Pathol; 2009 Oct; 62(10):896-902. PubMed ID: 19622517
[TBL] [Abstract][Full Text] [Related]
49. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations.
Pristauz G; Petru E; Stacher E; Geigl JB; Schwarzbraun T; Tsybrovskyy O; Winter R; Moinfar F
Histopathology; 2010 Dec; 57(6):877-84. PubMed ID: 21166701
[TBL] [Abstract][Full Text] [Related]
50. Analysis of the BRCA1 and BRCA2 genes in sporadic meningiomas.
Kirsch M; Zhu JJ; Black PM
Genes Chromosomes Cancer; 1997 Sep; 20(1):53-9. PubMed ID: 9290954
[TBL] [Abstract][Full Text] [Related]
51. [BRCA1 and BRCA2--breast cancer susceptibility genes].
Dagan E; Gershoni-Baruch R
Harefuah; 1997 Nov; 133(10):455-7. PubMed ID: 9418320
[No Abstract] [Full Text] [Related]
52. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.
Karp SE; Tonin PN; Bégin LR; Martinez JJ; Zhang JC; Pollak MN; Foulkes WD
Cancer; 1997 Aug; 80(3):435-41. PubMed ID: 9241077
[TBL] [Abstract][Full Text] [Related]
53. Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2.
Gaffney DK; Hemmersmeier J; Holden J; Marshall J; Smith LM; Avizonis V; Tran T; Neuhausen SL
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):539-46. PubMed ID: 11173152
[TBL] [Abstract][Full Text] [Related]
54. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases.
Malone KE; Daling JR; Neal C; Suter NM; O'Brien C; Cushing-Haugen K; Jonasdottir TJ; Thompson JD; Ostrander EA
Cancer; 2000 Mar; 88(6):1393-402. PubMed ID: 10717622
[TBL] [Abstract][Full Text] [Related]
55. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
Smith PD; Crossland S; Parker G; Osin P; Brooks L; Waller J; Philp E; Crompton MR; Gusterson BA; Allday MJ; Crook T
Oncogene; 1999 Apr; 18(15):2451-9. PubMed ID: 10229196
[TBL] [Abstract][Full Text] [Related]
56. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations.
Honrado E; Osorio A; Palacios J; Benitez J
Oncogene; 2006 Sep; 25(43):5837-45. PubMed ID: 16998498
[TBL] [Abstract][Full Text] [Related]
57. Hereditary breast cancer.
Hill A; McDermott E; O'Higgins N
Br J Surg; 1998 Aug; 85(8):1157. PubMed ID: 9718021
[No Abstract] [Full Text] [Related]
58. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.
Pierce LJ; Strawderman M; Narod SA; Oliviotto I; Eisen A; Dawson L; Gaffney D; Solin LJ; Nixon A; Garber J; Berg C; Isaacs C; Heimann R; Olopade OI; Haffty B; Weber BL
J Clin Oncol; 2000 Oct; 18(19):3360-9. PubMed ID: 11013276
[TBL] [Abstract][Full Text] [Related]
59. BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen.
Spillman MA; Bowcock AM
Oncogene; 1996 Oct; 13(8):1639-45. PubMed ID: 8895509
[TBL] [Abstract][Full Text] [Related]
60. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?
Phillips KA; Andrulis IL; Goodwin PJ
J Clin Oncol; 1999 Nov; 17(11):3653-63. PubMed ID: 10550164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
